Florida Fines Pharmacy Benefit Managers $12.66 Million

State regulators issued the penalties after market conduct examinations found violations in pharmacy benefit plan and participating pharmacy contracts.

Updated on Nov. 10, 2026 in Healthcare

Bold flat-color editorial illustration of a tall government building facade beside a geometric cross silhouette under flat daylight. — Florida Insurance Commissioner Mike Yaworsky announced more than $12.66 million in penalties against pharmacy benefit managers after state market conduct examinations. AI Illustration. Upload story photo >

Live Poll

Do you believe prescription drug middlemen are passing savings on to you?

Florida Insurance Commissioner Mike Yaworsky announced more than $12.66 million in penalties against pharmacy benefit managers following market conduct examinations by the Office of Insurance Regulation. Several PBMs are pushing back against the findings and pursuing litigation.

Why it matters

The examinations cited violations involving fair pricing models, network adequacy, pharmacy remittances, and unilateral contract changes, all areas tied to how prescription drug savings reach patients. The action is the enforcement stage of the Prescription Drug Reform Act that Governor Ron DeSantis signed in May 2023.

The Office of Insurance Regulation has issued more than $12.66 million in penalties from market conduct examinations of PBMs, which the state law allows it to conduct on a biennial basis. Examiners are still completing additional reviews, and some PBMs have not paid examiner invoices since January 2025.

The players

Office of Insurance Regulation (OIR)

Florida's state agency responsible for regulating insurance companies and conducting market conduct examinations of pharmacy benefit managers.

Mike Yaworsky

Florida's Insurance Commissioner, who announced the penalties and said PBMs must be held to transparency and accountability.

Ron DeSantis

Florida's governor, who signed the Prescription Drug Reform Act into law in May 2023.

The details

The Office of Insurance Regulation identified violations in pharmacy benefit plan and participating pharmacy contracts, including fair pricing models, network adequacy and fair access, pharmacy remittances, and prohibition of unilateral changes to pharmacy contracts. Many PBMs have taken or are taking corrective action, while others are cooperating only partially, which has delayed some examinations.

May 2023: Governor Ron DeSantis signed the Prescription Drug Reform Act.
January 2025: Examiner invoices began going unpaid by some examined PBMs.
November 9, 2026: OIR announced more than $12.66 million in PBM penalties.

Market Landscape

The penalties follow the 2023 Prescription Drug Reform Act, which gave Florida regulators biennial authority to examine PBMs. The enforcement comes as PBMs contest state oversight in court, shaping how pharmacy benefit pricing is policed in one of the nation's largest insurance markets.

Patients who rely on prescription drug benefits in Florida may see changes in how pharmacy pricing and rebates are passed along, depending on how PBMs respond to the penalties. Pharmacies in the state may also see contract terms shift as corrective actions are carried out.

The takeaway

Pharmacy benefit pricing is a less visible part of prescription costs, and state enforcement is now testing how much transparency regulators can require. Patients and pharmacies should watch whether corrective actions translate into lower out-of-pocket costs.